menu
    • menu
    [{"orgOrder":0,"company":"Medicines360","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Medicines360","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Medicines360 \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medicines360 \/ Undisclosed"},{"orgOrder":0,"company":"Medicines360","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Medicines360","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Medicines360 \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Medicines360 \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Medicines360

    Menu

    Medicines360

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medicines360

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Medicines360

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnanc...

                            Details : LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years. The system should be replaced after eight years if continued use is desired...

                            Product Name : Liletta

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medicines360

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Medicines360

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

                            Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Menorrhagia.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            August 22, 2018

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth